Cogent Biosciences' JAK2 V617F Inhibitor Shows Promising Preclinical Data at EHA 2026 — Cogent Biosciences, Inc.

Event summary

Cogent Biosciences presented preclinical data for CGT1145, a novel JAK2 V617F inhibitor, at the 2026 EHA Congress.
CGT1145 demonstrated >100x selectivity over JAK2 WT and JAK1/3 isoforms, with high oral bioavailability and low clearance.
The company plans to submit an Investigational New Drug (IND) application for CGT1145 in 2026.
JAK2 V617F is prevalent in 95% of polycythemia vera patients and 50% of primary myelofibrosis or essential thrombocythemia patients.

The big picture

Cogent Biosciences' presentation at EHA 2026 highlights the company's focus on developing precision therapies for genetically defined diseases. The preclinical data for CGT1145 underscores the potential of selective JAK2 V617F inhibitors to address unmet needs in myeloproliferative neoplasms, a market with significant therapeutic challenges. The strategic emphasis on mutant-selective inhibitors aligns with broader industry trends toward targeted therapies that minimize off-target effects and improve patient outcomes.

What we're watching

Regulatory Milestones: The pace at which Cogent Biosciences advances CGT1145 through the IND application process and subsequent clinical trials.
Competitive Positioning: Whether CGT1145's selectivity and tolerability profile can differentiate it from existing JAK inhibitors in the myeloproliferative neoplasms market.
Clinical Translation: How preclinical data for CGT1145 translates into clinical efficacy and safety outcomes in patients with JAK2 V617F-driven diseases.